One hip condition has real evidence; the rest do not
Avascular necrosis, during surgery
When part of the ball of the hip loses its blood supply, surgeons drill the dead bone (core decompression) and can add your own bone marrow cells at the same time. This is the one hip use with controlled results.[1][3]
Labral tears, impingement and tendons
Cells injected into the joint or tendon, or added during keyhole surgery. Here the evidence shows no benefit or does not exist.[2][4][5]
Hip arthritis
Wear-and-tear arthritis is a different condition. See stem cells for arthritis.
What to expect
The procedure
For avascular necrosis, one operation: marrow is taken from the pelvis and put into the drilled bone.[6][7] Patients describe anything from same-day discharge to two nights in hospital, and weight-bearing rules that range from walking the same day to three months off the leg.[8]
When it works, and how long it lasts
Patients describe the first change at two to three months, and the bone taking six to twelve months to heal.[8] In the trials, the benefit is measured in years, but it is not permanent: 4 of 21 patients in one trial had a hip replacement within five years.[9][10]
For avascular necrosis, cells added to surgery cut collapse
Does it work? For avascular necrosis caught early, adding cells to the drilling operation roughly halves the chance of collapse, though the guideline panel rated the certainty very low.[1] For labral tears, impingement and tendons, no benefit has been shown.
Where it is allowed
United States. No cell product is approved for any hip condition. The FDA names hip pain among the unapproved uses.[17][18]
Malaysia. Your own marrow used in the same operation can fall outside the product rules. Lab-grown and donor cells must be registered.[19]
Mexico. COFEPRIS has said stem cell treatments lack authorisation.[20]
Specialists. The American College of Rheumatology recommends strongly against stem cell injections for hip arthritis.[21]
Common questions
Is it better than core decompression alone?
That is the comparison the evidence answers, and it favours adding cells. No trial has tested cells for avascular necrosis without the drilling.[3][1][22]
Do more cells give a better result?
Only up to about a million cells, after which repair flattened. The source of the cells made no difference.[13]
Questions to ask a clinic
- Is this avascular necrosis, arthritis or a labral tear? The evidence is different for each.
- Has the ball of my hip started to collapse?
- Will the cells go in during core decompression, or as an injection on their own?
- How large is the area of dead bone, and what are my odds at that size?
- How long will I be on crutches?
- Does my insurance cover the cells, or only the drilling?
Sources
23 references
- Parikh RR, et al. Diagnosis and Treatment of Nontraumatic Osteonecrosis of the Femoral Head: A Systematic Review and Meta-Analyses for the ARCO Clinical Practice Guideline Development Workgroup. Medical sciences (Basel, Switzerland), 2026. Link
- Spicer S, et al. Bone marrow aspirate concentrate adjunct for acetabular labral tear repair: a systematic review and meta-analysis. Hip International, 2025. Link
- Novriansyah R, et al. Assessing the latest advances in bone marrow stem cell therapy for Avascular Necrosis hip: A comprehensive systematic review, meta-analysis, and meta-regression of randomized controlled trial studies. PloS One, 2025. Link
- Bremer T, et al. The efficacy of gluteal tendinopathy treatments: A systematic review. Clinical Rehabilitation, 2025. Link
- Nasser AM, et al. Proximal Hamstring Tendinopathy: A Systematic Review of Interventions. International Journal of Sports Physical Therapy, 2021. Link
- Gangji V, et al. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot study. The Journal of Bone and Joint Surgery. American Volume, 2004. Link
- Ma Y, et al. Efficacy of autologous bone marrow buffy coat grafting combined with core decompression in patients with avascular necrosis of femoral head: a prospective, double-blinded, randomized, controlled study. Stem Cell Research & Therapy, 2014. Link
- StemFinder review of first-hand patient accounts on Reddit and patient forums, 2026. Method
- Gangji V, et al. Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: Five year follow-up of a prospective controlled study. Bone, 2011. Link
- Gómez-Barrena E, et al. Osteonecrosis of the Femoral Head Safely Healed with Autologous, Expanded, Bone Marrow-Derived Mesenchymal Stromal Cells in a Multicentric Trial with Minimum 5 Years Follow-Up. Journal of Clinical Medicine, 2021. Link
- Hauzeur JP, et al. Inefficacy of autologous bone marrow concentrate in stage three osteonecrosis: a randomized controlled double-blind trial. International Orthopaedics, 2018. Link
- Saini U, et al. Core decompression combined with intralesional autologous bone marrow derived cell therapies for osteonecrosis of the femoral head in adults: A systematic review and meta-analysis. The Surgeon, 2023. Link
- Hernigou P, et al. Mesenchymal Stem Cell Therapy for Bone Repair of Human Hip Osteonecrosis with Bilateral Match-Control Evaluation: Impact of Tissue Source, Cell Count, Disease Stage, and Volume Size on 908 Hips. Cells, 2024. Link
- Jayankura M, et al. Does Adjunction of Autologous Osteoblastic Cells Improve the Results of Core Decompression in Early-stage Femoral Head Osteonecrosis? A Double-blind, Randomized Trial. Clinical Orthopaedics and Related Research, 2023. Link
- Eliasberg CD, et al. Complications Following Biologic Therapeutic Injections: A Multicenter Case Series. Arthroscopy, 2021. Link
- Siddiq BS, et al. Neither Bone Marrow Aspirate Concentrate nor Platelet-Rich Plasma Improves Patient-Reported Outcomes After Surgical Management of Acetabular Labral Tears; However, Bone Marrow Aspirate Concentrate May Be Effective for Moderate Cartilage Damage: A Systematic Review. Arthroscopy, Sports Medicine, and Rehabilitation, 2024. Link
- U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, 2026. Link
- U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. 2024. Link
- National Pharmaceutical Regulatory Agency, Ministry of Health Malaysia. Guidance Document and Guidelines for Registration of Cell and Gene Therapy Products (CGTPs) in Malaysia, Second Edition (September 2025). 2025. Link
- Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS). La COFEPRIS suspendió clínica del D.F. que ofrecía tratamientos con Células Madre sin aval científico. Gobierno de México, COFEPRIS (press release), 2015. Link
- Kolasinski SL, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis & rheumatology (Hoboken, N.J.), 2020. Link
- Andronic O, et al. Lack of Conclusive Evidence of the Benefit of Biologic Augmentation in Core Decompression for Nontraumatic Osteonecrosis of the Femoral Head: A Systematic Review. Arthroscopy, 2021. Link
- George T, et al. Orthobiologics as an adjunct in treatment of femoroacetabular impingement syndrome: cell-based therapies facilitate improved postoperative outcomes in the setting of acetabular chondral lesions-a systematic review. Knee Surgery, Sports Traumatology, Arthroscopy, 2023. Link



